Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1359795 | 0.99 | ESR1 (0.61) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL1359567 | 0.99 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL1358883 | 0.94 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL1359750 | 0.92 | ESR1 (0.59) | ESR1ESR2 | |
| SCHEMBL1358399 | 0.92 | ESR1 (0.59) | ESR1ESR2 | |
| SCHEMBL1360664 | 0.92 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL1359708 | 0.92 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL1359327 | 0.91 | ESR1 (0.63) | ESR1ESR2 | |
| SCHEMBL1359438 | 0.91 | ESR1 (0.63) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL1360314 | 0.91 | ESR1 (0.62) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217032-B2 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | ELI LILLY AND COMPANY (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | GPER1, ESR1, HSD17B11 | ESR1 2/4885ESR2 7/4885 |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | GPER1, ESR1, HSD17B11 | ESR1 2/4885ESR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.